{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T22:26:53Z","timestamp":1793485613120,"version":"4.5.0"},"reference-count":35,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2026,1,20]]},"abstract":"\n Importance<\/jats:title>\n Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce chronic kidney disease (CKD) progression in individuals with type 2 diabetes, CKD, or heart failure. However, their effects in those with stage 4 CKD or little to no albuminuria remain uncertain.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To assess whether estimated glomerular filtration rate (eGFR) or degree of albuminuria, measured by urinary albumin to creatinine ratio (UACR), modifies the effects of SGLT2 inhibitors on kidney outcomes.<\/jats:p>\n <\/jats:sec>\n \n Data Sources<\/jats:title>\n SGLT2 inhibitor trials participating in the SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium (SMART-C).<\/jats:p>\n <\/jats:sec>\n \n Study Selection<\/jats:title>\n Randomized, double-blind, placebo-controlled trials within SMART-C evaluating an SGLT2 inhibitor with label indications for reducing CKD progression including at least 500 participants in each group with at least 6 months of follow-up.<\/jats:p>\n <\/jats:sec>\n \n Data Extraction and Synthesis<\/jats:title>\n Treatment effects in individual trials were pooled using inverse variance\u2013weighted meta-analysis.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n CKD progression, defined as kidney failure, at least 50% reduction in eGFR, or death due to kidney failure. Other outcomes included annual rate of eGFR decline and kidney failure.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Among 70\u202f361 participants (mean [SD] age, 64.8 [8.7] years; 24\u202f595 [35.0%] females) in 10 randomized trials, 2314 (3.3%) experienced CKD progression and 988 (1.4%) reached kidney failure. SGLT2 inhibitors reduced the risk of CKD progression (25.4 vs 40.3 events per 1000 patient-years; hazard ratio [HR], 0.62 [95% CI, 0.57-0.68]), irrespective of baseline eGFR (HR of 0.61 [95% CI, 0.52-0.71] for eGFR \u226560 mL\/min\/1.73 m\n 2<\/jats:sup>\n ; 0.57 [95% CI, 0.47-0.70] for eGFR of 45 to &amp;lt;60 mL\/min\/1.73 m\n 2<\/jats:sup>\n ; 0.64 [95% CI, 0.54-0.75] for eGFR of 30 to &amp;lt;45 mL\/min\/1.73 m\n 2<\/jats:sup>\n ; and 0.71 [95% CI, 0.60-0.83] for eGFR &amp;lt;30 mL\/min\/1.73 m\n 2<\/jats:sup>\n ;\n P<\/jats:italic>\n for trend\u2009=\u2009.16) and baseline albuminuria (HR of 0.58 [95% CI, 0.44-0.76] for albuminuria \u226430 mg\/g; 0.74 [95% CI, 0.57-0.96] for &amp;gt;30-300 mg\/g; and 0.57 [95% CI, 0.52-0.64] for more than 300 mg\/g;\n P<\/jats:italic>\n for trend\u2009=\u2009.49). Although the magnitude of protection varied, SGLT2 inhibitors reduced the annual rate of eGFR decline across all eGFR and UACR subgroups, including when participants with and without diabetes were analyzed separately. SGLT2 inhibitors also reduced the risk of kidney failure alone (HR, 0.66 [95% CI, 0.58-0.75]).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this meta-analysis, SGLT2 inhibitors were found to lower the risk of CKD progression regardless of baseline eGFR or albuminuria, including in patients with stage 4 CKD or minimal albuminuria, supporting their routine use to improve kidney outcomes across the full spectrum of kidney function among patients with type 2 diabetes, CKD, or heart failure.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jama.2025.20834","type":"journal-article","created":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T00:30:24Z","timestamp":1762561824000},"page":"233","source":"Crossref","is-referenced-by-count":89,"title":["SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria"],"prefix":"10.1001","volume":"335","author":[{"given":"Brendon L.","family":"Neuen","sequence":"first","affiliation":[{"name":"The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia"},{"name":"Department of Renal Medicine, Royal North Shore Hospital, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Fletcher","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia"},{"name":"Department of Public Health and Primary Care, British Heart Foundation Cardiovascular Epidemiology Unit and Victor Phillip Dahdaleh Heart and Lung Research Institute, University of Cambridge, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan D.","family":"Anker","sequence":"additional","affiliation":[{"name":"Department of Cardiology (CVK) of German Heart Center Charit\u00e9, Institute of Health Center for Regenerative Therapies (BCRT), German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charit\u00e9 Universit\u00e4tsmedizin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[{"name":"Mount Sinai Heart, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[{"name":"Baylor Scott and White Research Institute, Temple, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Z. I.","family":"Cherney","sequence":"additional","affiliation":[{"name":"Toronto General Research Institute, University Health Network, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieran F.","family":"Docherty","sequence":"additional","affiliation":[{"name":"School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio E.","family":"Inzucchi","sequence":"additional","affiliation":[{"name":"Yale University School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meg J.","family":"Jardine","sequence":"additional","affiliation":[{"name":"NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth W.","family":"Mahaffey","sequence":"additional","affiliation":[{"name":"Stanford Center for Clinical Research, Department of Medicine, Stanford University, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Finnian R.","family":"McCausland","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren K.","family":"McGuire","sequence":"additional","affiliation":[{"name":"University of Texas Southwestern Medical Center, Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J. V.","family":"McMurray","sequence":"additional","affiliation":[{"name":"School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Neal","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia"},{"name":"Imperial College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milton","family":"Packer","sequence":"additional","affiliation":[{"name":"Imperial College London, London, United Kingdom"},{"name":"Baylor University Medical Center, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddharth M.","family":"Patel","sequence":"additional","affiliation":[{"name":"TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlado","family":"Perkovic","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc S.","family":"Sabatine","sequence":"additional","affiliation":[{"name":"TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca J.","family":"Sardell","sequence":"additional","affiliation":[{"name":"Renal Studies Group, Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health (NDPH), University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthiah","family":"Vaduganathan","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Wanner","sequence":"additional","affiliation":[{"name":"Renal Studies Group, Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health (NDPH), University of Oxford, Oxford, United Kingdom"},{"name":"University Hospital of W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Wheeler","sequence":"additional","affiliation":[{"name":"Department of Renal Medicine, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lorraine, Inserm and CHRU de Nancy, Vand\u0153uvre-l\u00e8s-Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Haynes","sequence":"additional","affiliation":[{"name":"Renal Studies Group, Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health (NDPH), University of Oxford, Oxford, United Kingdom"},{"name":"Oxford Kidney Unit, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Staplin","sequence":"additional","affiliation":[{"name":"Renal Studies Group, Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health (NDPH), University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G.","family":"Herrington","sequence":"additional","affiliation":[{"name":"Renal Studies Group, Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health (NDPH), University of Oxford, Oxford, United Kingdom"},{"name":"Oxford Kidney Unit, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiddo J. L.","family":"Heerspink","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia"},{"name":"Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, Groningen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium (SMART-C)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendon L","family":"Neuen","sequence":"additional","affiliation":[{"name":"for the SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium (SMART-C)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiddo JL","family":"Heerspink","sequence":"additional","affiliation":[{"name":"for the SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium (SMART-C)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan D","family":"Anker","sequence":"additional","affiliation":[{"name":"for the SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium (SMART-C)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak L","family":"Bhatt","sequence":"additional","affiliation":[{"name":"for the SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium (SMART-C)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[{"name":"for the SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium (SMART-C)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David ZI","family":"Cherney","sequence":"additional","affiliation":[{"name":"for the SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium (SMART-C)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieran F","family":"Docherty","sequence":"additional","affiliation":[{"name":"for the SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium (SMART-C)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian F","family":"Hernandez","sequence":"additional","affiliation":[{"name":"for the SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium (SMART-C)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G","family":"Herrington","sequence":"additional","affiliation":[{"name":"for the SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium (SMART-C)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio E","family":"Inzucchi","sequence":"additional","affiliation":[{"name":"for the SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium (SMART-C)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"James","sequence":"additional","affiliation":[{"name":"for the SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium (SMART-C)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meg J","family":"Jardine","sequence":"additional","affiliation":[{"name":"for the SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium (SMART-C)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth W","family":"Mahaffey","sequence":"additional","affiliation":[{"name":"for the SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium (SMART-C)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren K","family":"McGuire","sequence":"additional","affiliation":[{"name":"for the SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium (SMART-C)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John JV","family":"McMurray","sequence":"additional","affiliation":[{"name":"for the SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium (SMART-C)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Neal","sequence":"additional","affiliation":[{"name":"for the SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium (SMART-C)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milton","family":"Packer","sequence":"additional","affiliation":[{"name":"for the SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium (SMART-C)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddharth M","family":"Patel","sequence":"additional","affiliation":[{"name":"for the SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium (SMART-C)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlado","family":"Perkovic","sequence":"additional","affiliation":[{"name":"for the SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium (SMART-C)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc S","family":"Sabatine","sequence":"additional","affiliation":[{"name":"for the SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium (SMART-C)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Staplin","sequence":"additional","affiliation":[{"name":"for the SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium (SMART-C)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D","family":"Solomon","sequence":"additional","affiliation":[{"name":"for the SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium (SMART-C)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthiah","family":"Vaduganathan","sequence":"additional","affiliation":[{"name":"for the SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium (SMART-C)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Wanner","sequence":"additional","affiliation":[{"name":"for the SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium (SMART-C)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C","family":"Wheeler","sequence":"additional","affiliation":[{"name":"for the SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium (SMART-C)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[{"name":"for the SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium (SMART-C)"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10365","key":"joi250094r1","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.","volume":"400","author":"Nuffield Department of Population Health Renal Studies Group","year":"2022","journal-title":"Lancet"},{"issue":"4S","key":"joi250094r2","first-page":"S117","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease.","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","journal-title":"Kidney Int"},{"issue":"39","key":"joi250094r3","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","article-title":"2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.","volume":"44","author":"Marx","year":"2023","journal-title":"Eur Heart J"},{"key":"joi250094r4","doi-asserted-by":"publisher","first-page":"S179","DOI":"10.2337\/dc24-S010","article-title":"10. Cardiovascular disease and risk management: standards of care in diabetes: 2024.","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2024","journal-title":"Diabetes Care"},{"issue":"1","key":"joi250094r5","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.kint.2017.06.017","article-title":"Pooled analysis of phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin.","volume":"93","author":"Cherney","year":"2018","journal-title":"Kidney Int"},{"issue":"12","key":"joi250094r6","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.2337\/dc22-0614","article-title":"Prescription patterns of cardiovascular- and kidney-protective therapies among patients with type 2 diabetes and chronic kidney disease.","volume":"45","author":"Lamprea-Montealegre","year":"2022","journal-title":"Diabetes Care"},{"issue":"2","key":"joi250094r8","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jcjd.2025.01.004","article-title":"Chronic kidney disease in diabetes: a clinical practice guideline.","volume":"49","author":"Tobe","year":"2025","journal-title":"Can J Diabetes"},{"key":"joi250094r9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-080257","article-title":"Sodium-glucose cotransporter-2 (SGLT-2) inhibitors for adults with chronic kidney disease: a clinical practice guideline.","volume":"387","author":"Agarwal","year":"2024","journal-title":"BMJ"},{"key":"joi250094r10","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.20835","article-title":"Effects of sodium glucose cotransporter 2 inhibitors by diabetes status and level of albuminuria: a meta-analysis.","author":"Staplin","year":"2025","journal-title":"JAMA"},{"key":"joi250094r11","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"22","key":"joi250094r12","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"joi250094r13","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes.","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"joi250094r14","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes.","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"joi250094r15","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1161\/CIRCULATIONAHA.120.051783","article-title":"Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial.","volume":"143","author":"Packer","year":"2021","journal-title":"Circulation"},{"issue":"16","key":"joi250094r16","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction.","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"issue":"21","key":"joi250094r17","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction.","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"issue":"12","key":"joi250094r18","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction.","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"issue":"24","key":"joi250094r19","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"joi250094r20","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease.","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"joi250094r21","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease.","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"issue":"16","key":"joi250094r22","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1056\/NEJMoa2314051","article-title":"Empagliflozin after acute myocardial infarction.","volume":"390","author":"Butler","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"joi250094r23","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2300286","article-title":"Dapagliflozin in myocardial infarction without diabetes or heart failure.","volume":"3","author":"James","year":"2024","journal-title":"NEJM Evid"},{"issue":"7","key":"joi250094r24","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1038\/s41591-023-02418-0","article-title":"A meta-analysis of GFR slope as a surrogate endpoint for kidney failure.","volume":"29","author":"Inker","year":"2023","journal-title":"Nat Med"},{"issue":"8","key":"joi250094r25","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S2213-8587(24)00155-4","article-title":"Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials.","volume":"12","author":"Apperloo","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"23","key":"joi250094r26","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1161\/CIRCULATIONAHA.124.069568","article-title":"Sodium-glucose cotransporter-2 inhibitors and major adverse cardiovascular outcomes: a SMART-C Collaborative meta-analysis.","volume":"149","author":"Patel","year":"2024","journal-title":"Circulation"},{"issue":"1","key":"joi250094r27","doi-asserted-by":"crossref","first-page":"S239","DOI":"10.2337\/dc25-S011","article-title":"11. Chronic kidney disease and risk management: standards of care in diabetes: 2025.","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","journal-title":"Diabetes Care"},{"issue":"37","key":"joi250094r28","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"issue":"13","key":"joi250094r29","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1001\/jama.2023.17002","article-title":"Estimated glomerular filtration rate, albuminuria, and adverse outcomes: an individual-participant data meta-analysis.","volume":"330","author":"Grams","year":"2023","journal-title":"JAMA"},{"issue":"10","key":"joi250094r30","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications.","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"issue":"11","key":"joi250094r31","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","article-title":"SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis.","volume":"7","author":"Neuen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"joi250094r32","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/s12325-020-01568-8","article-title":"Burden of chronic kidney disease by KDIGO categories of glomerular filtration rate and albuminuria: a systematic review.","volume":"38","author":"Murton","year":"2021","journal-title":"Adv Ther"},{"issue":"1","key":"joi250094r33","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/dom.12583","article-title":"Early renin-angiotensin system intervention is more beneficial than late intervention in delaying end-stage renal disease in patients with type 2 diabetes.","volume":"18","author":"Schievink","year":"2016","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"joi250094r34","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1681\/ASN.2021070948","article-title":"Acute treatment effects on GFR in randomized clinical trials of kidney disease progression.","volume":"33","author":"Neuen","year":"2022","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"joi250094r35","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1093\/ndt\/gfaf046","article-title":"Rationale and design of the Renal Lifecycle Trial assessing the effect of dapagliflozin on cardiorenal outcomes in severe chronic kidney disease.","volume":"40","author":"Bakker","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"joi250094r7","unstructured":"National Institute for Health and Care Excellence (NICE). Type 2 diabetes in adults: management. Accessed August 1, 2025. https:\/\/www.nice.org.uk\/guidance\/ng28\/chapter\/recommendations#chronic-kidney-disease"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2841163\/jama_neuen_2025_oi_250094_1767896097.22085.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T16:00:55Z","timestamp":1768924855000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2841163"}},"subtitle":["A Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,1,20]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2025.20834","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,20]]}}}